February 22, 2021 -- Johnson & Johnson announced it has submitted Janssen's investigational single-dose COVID-19 vaccine candidate to the World Health Organization (WHO) for emergency use listing.
The submission, which includes interim efficacy and safety results from the phase III Ensemble clinical trial, marks the completion of the firm's rolling submission of its vaccine candidate to the WHO.
The emergency listing is a prerequisite to supply vaccines to the new Covax facility to procure and distribute COVID-19 vaccines in 190 participating countries, including 92 lower-income countries.
The firm has rolling submissions for the investigational single-dose COVID-19 vaccine initiated in several countries.
Copyright © 2021 scienceboard.net